» About Us » Leadership » Roger A. Hubbard, PhD Client Login | Email | Phone: 1.865.380.9746

Roger A. Hubbard, PhD

Roger A. Hubbard, PhD

Founder, President, Chief Executive Officer

Dr. Hubbard founded MPLN in 1989 after completing doctoral studies in biochemistry and molecular biology at the Medical University of South Carolina in Charleston and subsequent training in the Department of Microbiology and Immunology at the University of Arizona Health Sciences Center in Tucson. He holds the academic rank of adjunct associate professor in the Department of Pathology at the University of Tennessee Medical Center in Knoxville and holds the High-complexity Clinical Laboratory Director certification from the American Board of Bioanalysis.

Dr. Hubbard is a laboratory inspector within the Laboratory Accreditation Program of the College of American Pathologists. Dr. Hubbard is a clinical scientist member of the American Society of Clinical Pathologists. He has written numerous publications in the areas of clinical flow cytometry, molecular immunology, infectious disease diagnostic testing and molecular oncology.


  1. Frantz C, Sekora DM, Henley DC, Huang C, Pan Q, Quigley NB, Gorman E, Hubbard RA, Mirza I (2007). Comparative Evaluation of Three JAK2 V617F Mutation Detection Methods. American Journal of Clinical Pathology 128:865-874.
  2. Hubbard RA (2003). Human papillomavirus testing methods. Archives Pathology Laboratory Medicine 127:940.
  3. Seabrook J, Hubbard RA (2003). Achieving quality reproducible results and maintaining compliance in molecular diagnostic testing of human papillomavirus. Archives of Pathology Laboratory Medicine 127:978.
  4. Modarress KJ, Cullen AP, Jaffurs WJ, Troutman GL, Mousavi N, Hubbard RA, Henderson S, Lorincz AL (1999). Detection of Chlamydia trachomatis and Neisseria gonnorrhoeae in swab specimens by the Hybrid Capture II and PACE 2 nucleic acid probe tests. Sexually Transmitted Diseases 26:303.
  5. Dedeoglu F, Hubbard RA, Schluter SF, Marchalonis JJ (1992). T-cell receptors of man and mouse studied with antibodies against synthetic peptides. Experimental and Clinical Immunogenetics 9:95.
  6. Ross CR, Hubbard RA, Schluter SF, Diamanduros A, Wang AC, Marchalonis JJ (1989). Antibodies to synthetic peptides corresponding to variable region first framework (Fr1) segments of T cell receptors: Detection of T cell products and cross-reactions with classical immunoglobulins. Immunologic Research 8:81.
  7. Hubbard RA, Speidel MT, Marchalonis JJ, Cone RC (1989). A monoclonal antigen binding T cell immunoprotein is distinct from classical immunoglobulins and T cell receptor heterodimers. Molecular Immunology 26:447.
  8. Marchalonis JJ, Schluter SF, Hubbard RA, McCabe C, Allen RC (1988). Immunoglobulin epitopes defined by synthetic peptides corresponding to joining region sequence: Conservation of determinants and dependence upon the presence of an arginyl or lysyl residue for cross-reaction between light chains and T cell receptor chains. Molecular Immunology 25:771.
  9. Marchalonis JJ, Schluter SF, Hubbard RA, Diamanduros A, Barker WC, Pumphrey RSH (1987). Conservation of immunoglobulin variable and joining region structure and the design of universal anti-immunoglobulin antibodies reactive with antigen-binding T cell receptors. International Reviews in Immunology 3:241.
  10. Schluter SF, Rosenshein IF, Hubbard RA, Marchalonis JJ (1987). Conservation among vertebrate immunoglobulin chains detected by antibodies to a synthetic joining segment peptide. Biochemical and Biophysical Research Communications 145:699.
  11. Fuson EW, Cole AJ, Hubbard RA (1985). Antibody dependent cell-mediated cytolysis by human lymphocytes: A regulatory role for the sheep red blood cell receptor. Journal of Clinical and Laboratory Immunology 17:183.
  12. Fuson EW, Hubbard RA, Sugantharaj DG, Andrews RB, Beard MR, Whittaker RL (1983). Antibody dependent cell mediated cytotoxicity; effectors, signals and mechanisms. Survey of Immunological Research 2:327.
  13. Hunt CJ, Marchalonis JJ, Hubbard RA, McDonald JK (1983). Dipeptidyl aminopeptidase IV activity in selected human leukemia/lymphoma T and B in vitro cell lines. In: Leukemia Reviews International, Vol. 1. Advances in Comparative Leukemia Research. M.A. Rich and D.S. Yohn, eds., Marcel Dekker, Inc., New York. pp. 186.
  14. Fuson EW, Sugantharaj DG, Hubbard RA (1982). Nonspecific human lymphocyte mediated cytotoxicity by immobilized IgG aggregate: Regulation by a suppressor cell. Journal of Clinical and Laboratory Immunology 7:55.
  15. Fuson EW, Shaw MW, Hubbard RA, Sugantharaj DG, Lamon EW (1981). Antibody dependent cell-mediated cytotoxicity by human lymphocytes. II. Comparison with polymorphonuclear leukocytes against erythrocyte and nucleated target cells. Experimental Hematology 9:197.
  16. Hubbard RA, Aggio MC, Lozzio BB, Wust CJ (1981). Correlation of circulating immune complexes and disease status in patients with leukemia. Clinical and Experimental Immunology 43:46.
  17. Fuson EW, Shaw MW, Hubbard RA, Lamon EW (1979). Antibody-antigen complex stimulated lysis of nonsensitized sheep red cells by human lymphocytes. I. Requirement for IgG complexes. Clinical and Experimental Immunology 38:158.
  18. Aggio MC, Hubbard RA, Lozzio BB, Krauss S (1978). Circulating immune complexes in human leukemia and lymphoma. Their prognostic value. Blood 52:237.